Table 4.
Dose-modification guidelines for TiPN and BiPN based on clinical practice and expert opinion*
*For thalidomide, see: http://www.emea.europa.eu/humandocs/Humans/EPAR/thalidomidecelgene/thalidomidecelgene.htm; for bortezomib, see: http://www.emea.europa.eu/humandocs/Humans/EPAR/Velcade/velcade.htm
